Jun 24 2010
International Stem Cell Corporation (OTCBB:ISCO), www.intlstemcell.com, a California-based biotechnology company focused on therapeutic and research products, congratulates Advanced Cell Technology, Inc. (ACT) on the issuance of its recent patent, U.S. Patent Number 7,736,896, covering a method for producing retinal pigment epithelial cells.
“This is just one more example of the remarkable advancement in science toward the treatment of life's more dreaded diseases, and we are proud to be one of the leading pioneers in that effort”
As licensee of the retinal cell technology covered by this ACT patent, ISCO looks forward to building on this discovery, either independently or in collaboration with ACT, with the goal of advancing the search for treatment of such diseases as Macular Degeneration and Retinitis Pigmentosa, leading causes of blindness in adults, both in the US and the World.
In addition to its licensed interest in the ACT patent, ISCO is developing its own proprietary technology for creating and implanting retinal pigment epithelial (RPE) cells that may be usable either in conjunction with its licensed technology from ACT or independently.
"This is just one more example of the remarkable advancement in science toward the treatment of life's more dreaded diseases, and we are proud to be one of the leading pioneers in that effort," said Kenneth Aldrich, Chairman of ISCO.
SOURCE International Stem Cell Corporation
Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC